Testing Agents for Prevention or Reversal of Type 1 Diabetes in Rodents

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Grant, Christian W ^b   Moran Paul, Catherine M ^b   Duclos, Shane K ^b   Guberski, Dennis L ^b   Arreaza Rubín, Guillermo ^a   Spain, Lisa M ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b Biomedical Research Models (BRM) Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANTIDIABETIC AGENT; CD3 ANTIBODY; CELASTROL; CYCLOSPORIN A; DEXAMETHASONE; DT 22669; GLUCAGON LIKE PEPTIDE 1; ISO 092; ISOPHANE INSULIN; TETRACOSENOYL SULFATIDE; TREGITOPE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; BIOBREEDING DIABETES PRONE RAT; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; MULTIPLE AUTOIMMUNE DISEASE PRONE RAT; NONHUMAN; NONOBESE DIABETIC MOUSE; PERITONITIS; RANDOMIZATION; RAT; RAT STRAIN; REVIEW;

ANIMALS; ANTIBODIES; ANTIGENS, CD3; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED NOD; RATS; REMISSION INDUCTION; TRITERPENES;

EID: 84883343953     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072989     Document Type: Review

References (61)

1. Makino S, Kunimoto K, Muraoka Y, Mizushima Y, Katagiri K, et al. (1980) Breeding of a non-obese, diabetic strain of mice. Jikken Dobutsu Exp Anim 29: 1-13.
2. Nakhooda AF, Like AA, Chappel CI, Wei CN, Marliss EB, (1978) The spontaneously diabetic Wistar rat (the "BB" rat). Studies prior to and during development of the overt syndrome. Diabetologia 14: 199-207. doi:10.1007/BF00429781. PubMed: 350681.
3. Mordes JP, Guberski DL, Leif JH, Woda BA, Flanagan JF, et al. (2005) LEW.1WR1 rats develop autoimmune diabetes spontaneously and in response to environmental perturbation. Diabetes 54: 2727-2733. doi:10.2337/diabetes.54.9.2727. PubMed: 16123363.
4. Atkinson MA, (2011) Evaluating preclinical efficacy. Sci Transl Med 3: 96cm22. PubMed: 21849661.
5. Fiorina P, Vergani A, Dada S, Jurewicz M, Wong M, et al. (2008) Targeting CD22 reprograms B-cells and reverses autoimmune diabetes. Diabetes 57: 3013-3024. doi:10.2337/db08-0420. PubMed: 18689692.
6. Vergani A, D'Addio F, Jurewicz M, Petrelli A, Watanabe T, et al. (2010) A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice. Diabetes 59: 2253-2264. doi:10.2337/db09-1264. PubMed: 20805386.
7. Ablamunits V, Henegariu O, Hansen JB, Opare-Addo L, Preston-Hurlburt P, et al. (2012) Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 61: 145-154. doi:10.2337/db11-1033. PubMed: 22043003.
8. Perone MJ, Bertera S, Shufesky WJ, Divito SJ, Montecalvo A, et al. (2009) Suppression of autoimmune diabetes by soluble galectin-1. J Immunol 182: 2641-2653. doi:10.4049/jimmunol.0800839. PubMed: 19234158.
9. Tian B, Hao J, Zhang Y, Tian L, Yi H, et al. (2009) Upregulating CD4+CD25+FOXP3+ regulatory T cells in pancreatic lymph nodes in diabetic NOD mice by adjuvant immunotherapy. Transplantation 87: 198-206. doi:10.1097/TP.0b013e3181933261. PubMed: 19155973.
10. Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, et al. (2009) Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 58: 1302-1311. doi:10.2337/db08-1113. PubMed: 19289457.
11. Zhao Y, Lin B, Darflinger R, Zhang Y, Holterman MJ, et al. (2009) Human cord blood stem cell-modulated regulatory T lymphocytes reverse the autoimmune-caused type 1 diabetes in nonobese diabetic (NOD) mice. PLOS ONE 4: e4226. doi:10.1371/journal.pone.0004226. PubMed: 19156219.
12. Grinberg-Bleyer Y, Baeyens A, You S, Elhage R, Fourcade G, et al. (2010) IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 207: 1871-1878. doi:10.1084/jem.20100209. PubMed: 20679400.
13. Kosiewicz MM, Auci DL, Fagone P, Mangano K, Caponnetto S, et al. (2011) HE3286, an orally bioavailable synthetic analogue of an active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse. Eur J Pharmacol 658: 257-262. doi:10.1016/j.ejphar.2011.02.016. PubMed: 21371458.
14. Moore DJ, Zienkiewicz J, Kendall PL, Liu D, Liu X, et al. (2010) In vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetes. PLOS ONE 5: e13235. doi:10.1371/journal.pone.0013235. PubMed: 20949090.
15. Yamada A, Ishimaru N, Arakaki R, Katunuma N, Hayashi Y, (2010) Cathepsin L inhibition prevents murine autoimmune diabetes via suppression of CD8(+) T cell activity. PLOS ONE 5: e12894. doi:10.1371/journal.pone.0012894. PubMed: 20877570.
16. McGuire HM, Walters S, Vogelzang A, Lee CM, Webster KE, et al. (2011) Interleukin-21 is critically required in autoimmune and allogeneic responses to islet tissue in murine models. Diabetes 60: 867-875. doi:10.2337/db10-1157. PubMed: 21357471.
17. Lee LF, Logronio K, Tu GH, Zhai W, Ni I, et al. (2012) Anti-IL-7 receptor-alpha reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proc Natl Acad Sci U S A 109: 12674-12679. doi:10.1073/pnas.1203795109. PubMed: 22733769.
18. Davoodi-Semiromi A, Wasserfall CH, Xia CQ, Cooper-DeHoff RM, Wabitsch M, et al. (2012) The tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD mice. PLOS ONE 7: e36079. doi:10.1371/journal.pone.0036079. PubMed: 22615750.
19. Sobel DO, Henzke A, Abbassi V, (2010) Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus. Acta Diabetol 47: 243-250. doi:10.1007/s00592-010-0188-2. PubMed: 20440520.
20. Davalli AM, Perego C, Folli FB, Bosi E, (2012) Long-lasting remission of type 1 diabetes following treatment with topiramate for generalized seizures. Acta Diabetol 49: 75-79. doi:10.1007/s00592-011-0268-y. PubMed: 21336872.
21. Yi Z, Diz R, Martin AJ, Morillon YM, Kline DE, et al. (2012) Long-term remission of diabetes in NOD mice is induced by nondepleting anti-CD4 and anti-CD8 antibodies. Diabetes 61: 2871-2880. doi:10.2337/db12-0098. PubMed: 22751694.
22. Wang M, Racine JJ, Song X, Li X, Nair I, et al. (2012) Mixed chimerism and growth factors augment beta cell regeneration and reverse late-stage type 1 diabetes. Sci Transl Med 4: 133ra159.
23. Takiishi T, Korf H, Van Belle TL, Robert S, Grieco FA, et al. (2012) Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 122: 1717-1725. doi:10.1172/JCI60530. PubMed: 22484814.
24. Wan X, Guloglu FB, Vanmorlan AM, Rowland LM, Zaghouani S, et al. (2013) Recovery from Overt Type 1 Diabetes Ensues When Immune Tolerance and beta Cell Formation Are Coupled with Regeneration of Endothelial Cells in the Pancreatic Islets. Diabetes.
25. Hu C, Ding H, Zhang X, Wong FS, Wen L, (2013) Combination treatment with anti-CD20 and oral anti-CD3 prevents and reverses autoimmune diabetes. Diabetes, 62: 2849-58. PubMed: 23447122.
26. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, et al. (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490: 187-191. doi:10.1038/nature11556. PubMed: 23060188.
27. Grant CW, Duclos SK, Moran-Paul CM, Yahalom B, Tirabassi RS, et al. (2012) Development of Standardized Insulin Treatment Protocols for Spontaneous Rodent Models of Type 1 Diabetes. Comp Med 62: 381-390. PubMed: 23114041.
28. Institute for Laboratory Animal Research (2011) Guide for the care and use of laboratory animals. Washington, DC: National Academies Press.
29. The Office of Laboratory Animal Welfare (OLAW) (2002) Public Health Services Policy on Humane Care and Use of Laboratory Animals. Bethesda, MD: National Institutes of Health.
30. Tirabassi RS, Guberski DL, Blankenhorn EP, Leif JH, Woda BA, et al. (2010) Infection with viruses from several families triggers autoimmune diabetes in LEW*1WR1 rats: prevention of diabetes by maternal immunization. Diabetes 59: 110-118. doi:10.2337/db09-0255. PubMed: 19794063.
31. Londono P, Komura A, Hara N, Zipris D, (2010) Brief dexamethasone treatment during acute infection prevents virus-induced autoimmune diabetes. Clin Immunol 135: 401-411. doi:10.1016/j.clim.2010.01.007. PubMed: 20167539.
32. Pozzilli P, Signore A, Williams AJ, Beales PE, (1993) NOD mouse colonies around the world- recent facts and figures. Immunol Today 14: 193-196. doi:10.1016/0167-5699(93)90160-M. PubMed: 8517916.
33. Yang ZD, Chen M, Wu R, McDuffie M, Nadler JL, (2002) The anti-inflammatory compound lisofylline prevents Type I diabetes in non-obese diabetic mice. Diabetologia 45: 1307-1314. doi:10.1007/s00125-002-0901-y. PubMed: 12242464.
34. Yang Z, Chen M, Fialkow LB, Ellett JD, Wu R, et al. (2003) Inhibition of STAT4 activation by lisofylline is associated with the protection of autoimmune diabetes. Ann N Y Acad Sci 1005: 409-411. doi:10.1196/annals.1288.069. PubMed: 14679102.
35. Yang Z, Chen M, Ellett JD, Fialkow LB, Carter JD, et al. (2004) The novel anti-inflammatory agent lisofylline prevents autoimmune diabetic recurrence after islet transplantation. Transplantation 77: 55-60. doi:10.1097/01.TP.0000104844.48064.81. PubMed: 14724435.
36. Yang Z, Chen M, Carter JD, Nunemaker CS, Garmey JC, et al. (2006) Combined treatment with lisofylline and exendin-4 reverses autoimmune diabetes. Biochem Biophys Res Commun 344: 1017-1022. doi:10.1016/j.bbrc.2006.03.177. PubMed: 16643856.
37. Jaworski MA, Honore L, Jewell LD, Mehta JG, McGuire-Clark P, et al. (1986) Cyclosporin prophylaxis induces long-term prevention of diabetes, and inhibits lymphocytic infiltration in multiple target tissues in the high-risk BB rat. Diabetes Res 3: 1-6. PubMed: 3514066.
38. Lewis EC, (2012) Expanding the clinical indications for alpha(1)-antitrypsin therapy. Mol Med 18: 957-970. PubMed: 22634722.
39. Ma H, Lu Y, Li H, Campbell-Thompson M, Parker M, et al. (2010) Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease. Diabetologia 53: 2198-2204. doi:10.1007/s00125-010-1829-2. PubMed: 20593162.
40. Lu Y, Tang M, Wasserfall C, Kou Z, Campbell-Thompson M, et al. (2006) Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum Gene Ther 17: 625-634. doi:10.1089/hum.2006.17.625. PubMed: 16776571.
41. Koulmanda M, Bhasin M, Hoffman L, Fan Z, Qipo A, et al. (2008) Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A 105: 16242-16247. doi:10.1073/pnas.0808031105. PubMed: 18852471.
42. Dagia NM, Kamath DV, Bhatt P, Gupte RD, Dadarkar SS, et al. (2009) A fluorinated analog of ISO-1 blocks the recognition and biological function of MIF and is orally efficacious in a murine model of colitis. Eur J Pharmacol 607: 201-212. doi:10.1016/j.ejphar.2009.02.031. PubMed: 19239912.
43. Stojanovic I, Saksida T, Nikolic I, Nicoletti F, Stosic-Grujicic S, (2012) Macrophage migration inhibitory factor deficiency protects pancreatic islets from cytokine-induced apoptosis in vitro. Clin Exp Immunol 169: 156-163. doi:10.1111/j.1365-2249.2012.04607.x. PubMed: 22774990.
44. Bojunga J, Kusterer K, Bacher M, Kurek R, Usadel KH, et al. (2003) Macrophage migration inhibitory factor and development of type-1 diabetes in non-obese diabetic mice. Cytokine 21: 179-186. doi:10.1016/S1043-4666(03)00076-0. PubMed: 12788306.
45. Subramanian L, Blumenfeld H, Tohn R, Ly D, Aguilera C, et al. (2012) NKT cells stimulated by long fatty acyl chain sulfatides significantly reduce the incidence of type 1 diabetes in nonobese diabetic mice [corrected]. PLOS ONE 7: e37771. doi:10.1371/journal.pone.0037771. PubMed: 22649557.
46. Halder RC, Aguilera C, Maricic I, Kumar V, (2007) Type II NKT cell-mediated anergy induction in type I NKT cells prevents inflammatory liver disease. J Clin Invest 117: 2302-2312. doi:10.1172/JCI31602. PubMed: 17641782.
47. Cascão R, Vidal B, Raquel H, Neves-Costa A, Figueiredo N, et al. (2012) Effective treatment of rat adjuvant-induced arthritis by celastrol. Autoimmun Rev 11: 856-862. doi:10.1016/j.autrev.2012.02.022. PubMed: 22415021.
48. Kusy S, Ghosn EE, Herzenberg LA, Contag CH, (2012) Development of B cells and erythrocytes is specifically impaired by the drug celastrol in mice. PLOS ONE 7: e35733. doi:10.1371/journal.pone.0035733. PubMed: 22545133.
49. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, et al. (2008) Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 112: 3303-3311. doi:10.1182/blood-2008-02-138073. PubMed: 18660382.
50. van der Marel S, Majowicz A, Kwikkers K, van Logtenstein R, te Velde AA, et al. (2012) Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. World J Gastroenterol WJG 18: 4288-4299. doi:10.3748/wjg.v18.i32.4288. PubMed: 22969191.
51. Lamont BJ, Drucker DJ, (2008) Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 57: 190-198. PubMed: 17928394.
52. Vaidya HB, Goyal RK, (2008) Glucagon like peptides-1 modulators as newer target for diabetes. Curr Drug Targets 9: 911-920. doi:10.2174/138945008785909284. PubMed: 18855626.
53. Xue S, Wasserfall C, Parker M, McGrail S, McGrail K, et al. (2010) Exendin-4 treatment of nonobese diabetic mice increases beta-cell proliferation and fractional insulin reactive area. J Diabetes Complications 24: 163-167. doi:10.1016/j.jdiacomp.2008.12.004. PubMed: 19217320.
54. Castillo GM, Reichstetter S, Bolotin EM, (2012) Extending residence time and stability of peptides by protected graft copolymer (PGC) excipient: GLP-1 example. Pharm Res 29: 306-318. doi:10.1007/s11095-011-0542-2. PubMed: 21830140.
55. Mehta DS, Christmas RA, Waldmann H, Rosenzweig M, (2010) Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice. Immunology 130: 103-113. doi:10.1111/j.1365-2567.2009.03217.x. PubMed: 20059577.
56. Sarikonda G, Sachithanantham S, Manenkova Y, Kupfer T, Posgai A, et al. (2013) Transient B-cell depletion with anti-CD20 in combination with proinsulin DNA vaccine or oral insulin: immunologic effects and efficacy in NOD mice. PLOS ONE 8: e54712. doi:10.1371/journal.pone.0054712. PubMed: 23405091.
57. Chen G, Han G, Wang J, Wang R, Xu R, et al. (2008) Essential roles of TGF-beta in anti-CD3 antibody therapy: reversal of diabetes in nonobese diabetic mice independent of Foxp3+CD4+ regulatory T cells. J Leukoc Biol 83: 280-287. PubMed: 18029395.
58. Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, et al. (2007) Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 148: 5136-5144. doi:10.1210/en.2007-0358. PubMed: 17673522.
59. Phillips JM, O'Reilly L, Bland C, Foulis AK, Cooke A, (2007) Patients with chronic pancreatitis have islet progenitor cells in their ducts, but reversal of overt diabetes in NOD mice by anti-CD3 shows no evidence for islet regeneration. Diabetes 56: 634-640. doi:10.2337/db06-0832. PubMed: 17327430.
60. Sosenko JM, Skyler JS, Herold KC, Palmer JP, (2012) The metabolic progression to type 1 diabetes as indicated by serial oral glucose tolerance testing in the Diabetes Prevention Trial-type 1. Diabetes 61: 1331-1337. doi:10.2337/db11-1660. PubMed: 22618768.
61. Skyler JS, Greenbaum CJ, Lachin JM, Leschek E, Rafkin-Mervis L, et al. (2008) Type 1 Diabetes TrialNet--an international collaborative clinical trials network. Ann N Y Acad Sci 1150: 14-24. doi:10.1196/annals.1447.054. PubMed: 19120262.